



**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST:     /     /

**SECTION I: PATIENT INFORMATION AND MEDICATION REQUESTED**

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

MEDICAID ID NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

DATE OF BIRTH:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

GENDER:  Male  Female

Drug Name:

Strength:

Dosing Directions:

Length of Therapy:

**SECTION II: PRESCRIBER INFORMATION**

LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

SPECIALTY:

NPI NUMBER:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PHONE NUMBER:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

FAX NUMBER:

				-					-						
--	--	--	--	---	--	--	--	--	---	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY**

- Does the patient have a confirmed diagnosis of Duchenne muscular dystrophy (DMD)?  Yes  No
- Exondys 51 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 51 skipping?  Yes  No
- Viltepro or Vyondys 53 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 53 skipping?  Yes  No
- Amondys 45 only:** Has genetic testing been completed to identify a mutation on the DMD gene amenable to exon 45 skipping?  Yes  No

*(Form continued on next page.)*

Fax to Prime Therapeutics Management if medications will be dispensed by a pharmacy and will be administered by the patient or caregiver at home.  
Phone: 1-866-675-7755  
Fax: 1-888-603-7696

Fax to DHHS if medication is dispensed/administered by the office or outpatient setting:  
Phone: 1-603-271-9384  
Fax: 1-603-314-8101





**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST:     /     /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (CONTINUED)**

5. Is the patient on a stable dose of corticosteroids?  Yes  No

If **yes** to question 5, list the medication and start date:

\_\_\_\_\_

If **no** to question 5, list the intolerance or contraindication:

6. Does the patient continue to have voluntary motor function?  Yes  No

7. Is the patient receiving physical and/or occupational therapy?  Yes  No

**Amondys 45, Vyondys 53, and Viltepso® only:**

8. Prior to initiating therapy, will serum cystatin C, urine dipstick, and urine protein-to-creatinine ratio be measured?  Yes  No

9. Will the urine dipstick and serum cystatin C be measured monthly and urine protein-to-creatinine ratio by assessed every 3 months during therapy?  Yes  No

**Viltepso® only:**

10. Does the patient have symptomatic cardiomyopathy?  Yes  No

11. Has a baseline assessment been completed with at least one of the following?  Yes  No

- Dystrophin level
- 6-minute walk test (6MWT) or other timed test
- Upper limb module (ULM) score
- North Star Ambulatory Assessment (NSAA)
- Forced vital capacity (FVC)% predicted

*(Form continued on the next page.)*

**Fax to Prime Therapeutics Management if medications will be dispensed by a pharmacy and will be administered by the patient or caregiver at home.**  
Phone: 1-866-675-7755  
Fax: 1-888-603-7696

**Fax to DHHS if medication is dispensed/administered by the office or outpatient setting:**  
Phone: 1-603-271-9384  
Fax: 1-603-314-8101





**New Hampshire Medicaid Fee-for-Service Program  
Prior Authorization Drug Approval Form**

Duchenne Muscular Dystrophy Agents

DATE OF MEDICATION REQUEST:     /     /

PATIENT LAST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

PATIENT FIRST NAME:

--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--	--

**SECTION III: CLINICAL HISTORY (CONTINUED)**

11. **For renewals (every 120 days):** Patient must demonstrate stability, improvement, or slowed rate of progression in one of the above assessments.

**Renewal assessment results:**

Please provide any additional information that would help in the decision-making process. **If additional space is needed, please use a separate sheet.**

**I certify that the information provided is accurate and complete to the best of my knowledge and I understand that any falsification, omission, or concealment of material fact may subject me to civil or criminal liability.**

**PRESCRIBER'S SIGNATURE:** \_\_\_\_\_ **DATE:** \_\_\_\_\_

**Facility where infusion is to be provided:** \_\_\_\_\_

**Medicaid provider number of facility:** \_\_\_\_\_

**Fax to Prime Therapeutics Management if medications will be dispensed by a pharmacy and will be administered by the patient or caregiver at home.**  
**Phone:** 1-866-675-7755  
**Fax:** 1-888-603-7696

**Fax to DHHS if medication is dispensed/administered by the office or outpatient setting:**  
**Phone:** 1-603-271-9384  
**Fax:** 1-603-314-8101

